title: Recovery from anthracycline cardiomyopathy after long-term support with a continuous flow left ventricular assist device.
abstract: We report the clinical course of a 16-year-old girl in remission from non-Hodgkin's lymphoma who presented in cardiogenic shock due to a severe anthracycline cardiomyopathy. The patient was initially stabilized using central extracorporeal membrane oxygenation support, followed by conversion to a left ventricular assist device. Unexpected evidence of cardiac recovery 9 months after implant enabled device weaning during a 3-month period, culminating in successful device explantation 1 year after implant. The patient survives 18 months after explant in New York Heart Association class I, on conventional heart failure medical management and metabolic therapy.
authors.affiliation: Department of Cardiology, Alfred Hospital, Victoria, Australia.
authors.forename: Mark
authors.initials: M
authors.lastname: Freilich
authors.forename: Dion
authors.initials: D
authors.lastname: Stub
authors.forename: Donald
authors.initials: D
authors.lastname: Esmore
authors.forename: Justin
authors.initials: J
authors.lastname: Negri
authors.forename: Robert
authors.initials: R
authors.lastname: Salamonsen
authors.forename: Peter
authors.initials: P
authors.lastname: Bergin
authors.forename: Angeline
authors.initials: A
authors.lastname: Leet
authors.forename: Meroula
authors.initials: M
authors.lastname: Richardson
authors.forename: Andrew
authors.initials: A
authors.lastname: Taylor
authors.forename: John
authors.initials: J
authors.lastname: Woodard
authors.forename: David
authors.initials: D
authors.lastname: Kaye
authors.forename: Franklin
authors.initials: F
authors.lastname: Rosenfeldt
mesh_terms: D000293:Adolescent; D018943:Anthracyclines / Q000009:adverse effects*; D000911:Antibodies, Monoclonal / Q000008:administration & dosage; D058846:Antibodies, Monoclonal, Murine-Derived; D000971:Antineoplastic Combined Chemotherapy Protocols / Q000008:administration & dosage / Q000627:therapeutic use; D003520:Cyclophosphamide / Q000008:administration & dosage; D004317:Doxorubicin / Q000008:administration & dosage; D015199:Extracorporeal Membrane Oxygenation; D005260:Female; D006353:Heart-Assist Devices; D006801:Humans; D016393:Lymphoma, B-Cell / Q000150:complications / Q000188:drug therapy; D011241:Prednisone / Q000008:administration & dosage; D000069283:Rituximab; D012770:Shock, Cardiogenic / Q000139:chemically induced* / Q000628:therapy; D014750:Vincristine / Q000008:administration & dosage
chemical_list: D018943:Anthracyclines; D000911:Antibodies, Monoclonal; D058846:Antibodies, Monoclonal, Murine-Derived; D000069283:Rituximab; D014750:Vincristine; D004317:Doxorubicin; D003520:Cyclophosphamide; D011241:Prednisone